Results 241 to 250 of about 4,794,371 (307)

The Stigma of self-report in health research: Time to reconsider what counts as "Objective". [PDF]

PLOS Glob Public Health
Alwan NA.
europepmc   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

A probabilistic approach to enhance the efficiency of case finding in hospital quality management: A case study using readmissions. [PDF]

PLoS One
Havranek MM, Bosancic A, Ammann E, Hug BL.   +3 more
europepmc   +1 more source

Medicine and other sciences: medical humanities

, 2019
Antonio Maconi, Roberta Lombardi, Mariateresa Dacquino   +2 more
openalex   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Exploring patient satisfaction with community pharmacy services in the United Arab Emirates: Implications for quality improvement. [PDF]

PLoS One
Kharaba Z, Alzoubi KH, Al-Azzam S, Al-Azayzih A, Abuhelwa AY, Jirjees F, Jarab A, Ramadan A, Altawalbeh SM, Rahhal D, Ahmed M, Ibrahim LA, Aldeyab MA, Alfoteih Y, Abuhammad S.   +14 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran. [PDF]

BMC Infect Dis
Abbasian A, SoleimanvandiAzar N, Baradaran HR, Ahmadi SAY, Eshrati B.   +4 more
europepmc   +1 more source